Track topics on Twitter Track topics that are important to you
Swiss-based Selexis has signed a commercial licence agreement to provide French biotechnology firm OSE Immunotherapeutics with access to high-performance research cell banks (RCBs) from its SUREtechno...
Regulatory News: OSE Immunotherapeutics SA (Paris:OSE) (ISIN: FR0012127173; Mnémo: OSE) today announced that following the recommendation by IDMC (independent experts) on the phase 3 clinical stud...
Regulatory News: This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170719005529/en/ OSE Immunotherapeutics SA (Paris:OSE) (ISIN: FR00...
NewsOSE Immunotherapeutics announces temporary pause of patient accrual while continuing treatment for patients already enrolled in Phase 3 clinical trial of Tedopi in advanced lung cancer.
OSE Immunotherapeutics Presents New Data on Anti-SIRPa (Effi-DEM), the Checkpoint Inhibitor blocking Pro-Tumor and Suppressor Myeloid Cells at "Advances in Immuno-Oncology Congress", London, May 15-16, 2017
Regulatory News: OSE Immunotherapeutics SA (Paris:OSE) (ISIN: FR0012127173; Mnémo: OSE) announced today that the Company presented in oral session significant data on Selective Anti-SIRPa OSE-172 ...
OSE Immunotherapeutics SA has halted recruitment in a Phase III trial of its cancer vaccine Tedopi (OSE2101).
The Feinstein Institute for Medical Research and Karolinska Institute granted Applied Immunotherapeutics Inc. (start-up developing treatments for autoimmune and inflammatory diseases) rights to discov...
OSE Immunotherapeutics has teamed up with Selexis in a new license agreement to support the development of its IL-7 antagonist for the treatment of IBD. In the end of last year, French OSE Immunothera...
Cancer Immunotherapetics differ fundamentally from most cancer therapies in that they involve manipulation of the immune system to induce an anti-tumor response. This fundamental difference results in...
M. A. suffers from hypogammaglobulinemia that has been complicated by refractory Mycoplasma hominis septic arthritis. He has been receiving the antibiotic valnemulin under Emergency Invest...
Innate Immunotherapeutics Limited is a public unlisted biopharmaceutical company based in Auckland, New Zealand. The company is focused on the development of a new generation of i...
Our ambition is to become a world leader in activation and regulation immunotherapies: OSE Immunotherapeutics is a biotechnology company led by world-class immunologists and focus...
AVANT Immunotherapeutics, Inc. is engaged in the discovery, development and commercialization of products that harness the human immune system to prevent and treat disease. The company is developing a...
We have published hundreds of Artielle ImmunoTherapeutics news stories on BioPortfolio along with dozens of Artielle ImmunoTherapeutics Clinical Trials and PubMed Articles about Artielle ImmunoTherapeutics for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Artielle ImmunoTherapeutics Companies in our database. You can also find out about relevant Artielle ImmunoTherapeutics Drugs and Medications on this site too.